Little Green Pharma Ltd (LGP) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Little Green Pharma Ltd A$0.04, price A$0.07, upside -41.8%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Little Green Pharma Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range A$0.0610 – A$0.8700 · fair‑value band A$0.0348 – A$0.0490 · the A$0.0720 price screens above the A$0.0419 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Little Green Pharma in your weekly email
Every Wednesday you see whether Little Green Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Little Green Pharma Ltd produces and sells cannabis-based medicinal products across Australia and Europe. The company also provides infrastructure to support plant genetics programs and the development of its flower portfolio. It sells its products through a network of wholesalers, pharmacies, clinics, and GPs (general practitioners).
Show more
Little Green Pharma Ltd produces and sells cannabis-based medicinal products across Australia and Europe. The company also provides infrastructure to support plant genetics programs and the development of its flower portfolio. It sells its products through a network of wholesalers, pharmacies, clinics, and GPs (general practitioners). The company was founded in 2016 and is based in Wembley, Australia.
Stock analysis
Little Green Pharma Ltd (LGP) currently trades at A$0.0720, while our model-based Fair Value estimate is A$0.0419, implying the stock looks roughly 71.9% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of A$0.0800 per share, and 1 of the 3 models we run sit above the A$0.0720 price.
Bear case: the Multiples group reads lowest at A$0.0300, and 2 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.0348 (bear) to A$0.0490 (bull), the price of A$0.0720 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Little Green Pharma Ltd reported revenue of A$42.4M in FY2026 versus A$14.0M in FY2022, a compound +31.8%/yr. Reported net income was −A$1.4M in FY2026.
Key figures
Market cap A$61.8M (≈ $43.4M) · P/S ratio 1.46 · Net margin −3.3% · Return on equity −1.7% · Return on assets (EBIT) −10.8% · Revenue (TTM) A$42.4M · Revenue growth (YoY) +20.4% · Free cash flow −A$790K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −42%, LGP screens richer than that median.
Fair Value models
Bear A$0.0348Fair Value A$0.0419Bull A$0.0490
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.4%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+279.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
352.6% (2021) → −4.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Little Green Pharma Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−42% · Below median
Profitability
Return on assets1% · Below median
Net margin (TTM)−3% · Below median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth20% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.52× · Cheapest 25%
P/S (TTM)1.02× · Cheaper than median
EV/EBITDA8.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)99· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Little Green Pharma Ltd Fair Value". https://www.fairvalue-calculator.com/stock/LGP
Frequently asked questions
Is Little Green Pharma Ltd (LGP) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of A$0.0419 versus a price of A$0.0720, about −42% upside (overvalued).
What is the fair value of LGP?
Our model-based fair value for Little Green Pharma Ltd is A$0.0419 (as of Sep 24, 2026), built from audited fundamentals. The current price: A$0.0720.
What is the quality score of LGP?
Little Green Pharma Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Little Green Pharma Ltd (LGP)?
Our model-based price target is the fair value of A$0.0419 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario A$0.0348, optimistic scenario A$0.0490. It is a calculation from audited fundamentals, not an analyst target.
What is the Little Green Pharma Ltd stock forecast for 2026?
Our models put fair value at A$0.0419, about −42% upside versus a price of A$0.0720 (overvalued). Cautious scenario A$0.0348, optimistic scenario A$0.0490. The calculation is refreshed regularly with new filings.
What is the revenue of Little Green Pharma Ltd (LGP)?
Little Green Pharma Ltd reported trailing-twelve-month revenue of about A$42.4M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Little Green Pharma Ltd (LGP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Little Green Pharma Ltd it is A$0.0419 per share (as of Sep 24, 2026), against a price of A$0.0720. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Little Green Pharma Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LGP trades above its calculated fair value: price A$0.0720, fair value A$0.0419, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LGP?
No. The price is what the market pays today (A$0.0720); the fair value is what the company's own numbers justify (A$0.0419). For Little Green Pharma Ltd the two are A$0.0301 per share apart. That gap is exactly why we show both numbers side by side.
How much is Little Green Pharma Ltd worth?
The market values Little Green Pharma Ltd at about A$61.8M (market capitalisation, as of Sep 24, 2026). Per share that is A$0.0720; our models calculate a fair value of A$0.0419 per share.
What do the bullish and bearish scenarios say about LGP?
Our models span a range for Little Green Pharma Ltd: cautious scenario A$0.0348, base A$0.0419, optimistic A$0.0490 per share (as of Sep 24, 2026, price A$0.0720). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Little Green Pharma Ltd (LGP)?
Balance-sheet figures for Little Green Pharma Ltd (as of Sep 24, 2026): return on equity −1.7%, debt of 0.03 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is LGP from its 52-week high?
Little Green Pharma Ltd trades at A$0.0720, about 49% below its 52-week high of A$0.1400 and 18% above the low of A$0.0610 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0419 is for.
Which stocks are comparable to Little Green Pharma Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Little Green Pharma Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price A$0.0720, calculated fair value A$0.0419 (−42%), Quality Score 44/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LGP calculated?
We run Little Green Pharma Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0419, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Little Green Pharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Little Green Pharma Ltd (LGP)?
The closing price on Sep 24, 2026 was A$0.0720. Our model-based fair value is A$0.0419, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Little Green Pharma Ltd right now?
The price sits above even our optimistic bull case (A$0.0490). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Little Green Pharma Ltd
How large is the market capitalisation of Little Green Pharma Ltd (LGP)?
The market capitalisation of Little Green Pharma Ltd is A$61.8M (≈ $43.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Little Green Pharma Ltd (LGP)?
The price-to-sales ratio of Little Green Pharma Ltd is 1.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Little Green Pharma Ltd (LGP)?
The net margin of Little Green Pharma Ltd is −3.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Little Green Pharma Ltd (LGP)?
The return on equity (ROE) of Little Green Pharma Ltd is −1.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Little Green Pharma Ltd (LGP)?
On an EBIT basis the return on assets of Little Green Pharma Ltd is −10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Little Green Pharma Ltd (LGP)?
Revenue at Little Green Pharma Ltd is growing +20.4% versus a year earlier (3y avg +29.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Little Green Pharma Ltd (LGP) generate?
The free cash flow of Little Green Pharma Ltd is −A$790K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Little Green Pharma Ltd (LGP) carry?
The net debt of Little Green Pharma Ltd is A$3.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Little Green Pharma Ltd in the live analysis
One click puts Little Green Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
